KOSDAQBiotech & Pharma043150

ValueAddedTechnologyCo

₩17,140▲ 5.74%2026-11-18 close
Market Cap
₩254.6B
Turnover
₩600M
Volume
30K
Shares out.
14.9M
PER
6.3×
PBR
0.5×
EPS
₩2,685
Dividend Yield
1.78%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩300 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating profit up, net loss in Q3 2026 at Value Added Technology

Operating profit rose 25.5% year on year in the third quarter of 2026, but the company swung to a KRW 3.6 billion net loss attributable to controlling shareholders, so whether net profit recovers is the next point to watch.

  1. 1

    Third-quarter 2026 revenue reached KRW 110.9 billion, up 10.8% year on year, while operating profit reached KRW 15.6 billion, up 25.5%, so operating profit grew faster than sales.

  2. 2

    Annual revenue rose for two consecutive years to KRW 426.4 billion in 2025, yet the operating margin fell from 20.2% in 2022 to 12.8% in 2025.

  3. 3

    Overseas sales dominate the mix. In the third quarter of 2026, European sales were KRW 32.9 billion, or 29.7% of the total, and Europe, the United States and South America together accounted for about 67.9%.

  4. 4

    The product mix is shifting. On a standalone basis in the third quarter of 2026, 3D product sales fell 11% while other product sales jumped 67%.

  5. 5

    The share price sits well below book value per share, but cumulative net profit attributable to controlling shareholders over the last four quarters is KRW 39.9 billion, so the multiple reading depends heavily on earnings swings.

02

Business structure

Value Added Technology makes dental diagnostic imaging equipment, with a line-up running from intraoral X-ray units through high-end CT systems to imaging and patient-consultation software.

It supplies products to more than 100 countries, and exports accounted for 92.6% of sales in 2025 against 7.4% from Korea. 3D diagnostic equipment is the largest product group, at 64.63% of sales in 2024, while 2D diagnostic equipment accounted for 13.46% and other items such as intraoral diagnostic devices, services and intraoral sensors made up 21.92% (FnGuide sales-mix data).

On a standalone basis in the third quarter of 2026, 2D sales were KRW 8.3 billion, up 1%, 3D sales were KRW 35.6 billion, down 11%, and other product sales were KRW 19.9 billion, up 67%.

By region in the third quarter of 2026, Europe contributed KRW 32.9 billion or 29.7% of sales, the United States KRW 31.6 billion, up 8.4%, and South America KRW 10.8 billion, up 18.8%. Czech sales rose 22.5% within Europe.

Its customers are dental clinics, and because the equipment improves diagnostic accuracy and treatment efficiency, replacement demand and new installations both support volume. R&D spending was KRW 13.67 billion in 2025, or 3.21% of sales (FnGuide).

In its mid-term strategy announced in September 2026, the company said it would combine its CT engineering with AI and software to extend from diagnosis and treatment into prevention and management.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩100.1B₩12.4B12.4%
2025Q4₩114.4B₩12.3B10.7%
2026Q1₩105.2B₩11B10.5%
2026Q2₩121.4B₩24.5B20.2%
2026Q3₩110.9B₩15.6B14.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩395.1B₩79.6B₩76.9B20.2%22.0%40.6%
2023₩384.9B₩64B₩51.7B16.6%13.0%41.7%
2024₩385.2B₩54B₩55.1B14.0%12.2%38.2%
2025₩426.4B₩54.8B₩40.1B12.8%8.1%38.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On the basis of filed results, revenue fell from KRW 395.1 billion in 2022 to KRW 384.9 billion in 2023, a 2.6% decline, and then rose to KRW 385.2 billion in 2024, up 0.1%, and KRW 426.4 billion in 2025, up 10.7%.

Revenue has therefore increased in 2024 and 2025, and 2025 is the largest year in the 2022 to 2025 period.

Operating profit moved the other way, falling from KRW 79.6 billion in 2022 to KRW 64 billion in 2023, down 19.6%, and to KRW 54 billion in 2024, down 15.7%, before recovering slightly to KRW 54.8 billion in 2025, up 1.5%.

The operating margin declined every year, from 20.2% in 2022 to 16.6%, 14.0% and 12.8% in 2025, so sales growth did not translate into better profitability.

Net profit attributable to controlling shareholders was KRW 76.9 billion in 2022, KRW 51.7 billion in 2023, down 32.7%, KRW 55.1 billion in 2024, up 6.6%, and KRW 40.1 billion in 2025, down 27.2%.

In 2025 operating profit rose while controlling-shareholder profit fell by more than a quarter, which points to swings below the operating line. Net profit including non-controlling interests was KRW 39.1 billion in 2025, close to the controlling figure.

Operating cash flow was KRW 60.3 billion in 2025, the highest of the four years and above that year's net profit.

Quarterly revenue went from KRW 100.1 billion in the third quarter of 2025 to KRW 114.4 billion in the fourth quarter, KRW 105.2 billion in the first quarter of 2026, KRW 121.4 billion in the second quarter and KRW 110.9 billion in the third quarter.

Operating profit was KRW 12.4 billion, KRW 12.3 billion, KRW 11 billion, KRW 24.5 billion and KRW 15.6 billion over the same five quarters, with the second quarter of 2026 up 122.6% on the prior quarter.

Net profit attributable to controlling shareholders moved from KRW 13.9 billion in the third quarter of 2025 to KRW 3.6 billion net loss in the third quarter of 2026, a swing into loss.

In its provisional third-quarter release, the company credited better cost of sales and operating efficiency for the profit gain, while pre-tax income before tax expense showed a loss of about KRW 2.1 billion. Cumulative net profit attributable to controlling shareholders over the last four quarters is KRW 39.9 billion.

05

Industry analysis

Dental diagnostic imaging equipment is essential for accuracy and clinical efficiency, so replacement of existing units and new installations at dental clinics are cited as the main support for demand.

The distinguishing feature of the third quarter of 2026 was that sales rose at the same time in Europe, the United States and South America. The company is pursuing premium 3D systems with large fields of view in advanced markets and mid-to-entry-level products in emerging markets.

In the same quarter, 3D sales declined while other product sales rose sharply, which suggests the mix of key products is changing. Equipment purchases depend on clinic investment capacity and replacement cycles, so when demand concentrates in a few countries, regional economic conditions matter more.

On competition, the company cites its CT engineering and a sales and service network across more than 100 countries as strengths. It adds local customer support and marketing to tailor offerings to regional clinical environments.

A broader industry trend is the digitization of equipment and its combination with software, which lines up with the company's AI and software strategy.

06

Outlook

The company plans to strengthen its premium 3D line, with large fields of view, in advanced markets, and to widen its customer base with mid-to-entry-level products in emerging markets. It intends to reinforce local customer support and marketing to respond to regional clinical conditions and demand.

Under the mid-term strategy announced in September 2026, the company plans to combine its CT development capability with AI and software and to extend its scope from diagnosis and treatment into prevention and management.

Third-quarter adjusted EBITDA was KRW 20.5 billion, up 14% year on year, with an EBITDA margin of 18.5%. Whether operating profit keeps growing faster than sales is the next item to check.

On products, the key questions are whether the 11% drop in 3D sales in the third quarter is temporary and whether the surge in other product sales continues.

Operating profit was KRW 24.5 billion in the second quarter of 2026 and KRW 15.6 billion in the third, so quarterly swings are large, and the cost structure behind them is the central item to verify in the next annual report. The size and timing of investment under the mid-term strategy will be confirmed in later disclosures.

07

Valuation

PER
6.3×
PBR
0.5×
ROE
7.9%
EPS
₩2,685
BPS
₩35,148
Dividend per share
₩300

The share price sits well below book value per share, which places it in a discount range relative to net assets. That multiple is, however, sensitive to the earnings base.

Cumulative net profit attributable to controlling shareholders over the last four quarters is KRW 39.9 billion, close to the KRW 40.1 billion recorded for 2025 as a full year. The multiples are calculated on the 2025 annual results, so the net loss of the third quarter of 2026 is not yet reflected.

Operating profit remains substantial, at KRW 54.8 billion in 2025 and KRW 24.5 billion in the second quarter of 2026. Net profit attributable to controlling shareholders moves much more because of items below operating profit, which makes earnings-based multiples volatile.

Operating cash flow was KRW 60.3 billion in 2025, above that year's net profit, so the gap between reported earnings and cash generation is worth tracking. The debt-to-equity ratio was 38.5% in 2025, lower than 40.6% in 2022. Dividends and shareholder returns are worth examining against how earnings move.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Operating profit outpaced sales growth

Third-quarter 2026 revenue of KRW 110.9 billion rose 10.8%, and operating profit of KRW 15.6 billion rose 25.5%. The operating margin reached 14.0%, up 1.6 percentage points from a year earlier. The company credited lower cost of sales and operating efficiency, and its adjusted EBITDA margin was 18.5%.

Growth across several overseas regions

European sales in the third quarter of 2026 rose 19.7% to KRW 32.9 billion, U.S. sales rose 8.4%, and South American sales rose 18.8%. Those three regions together produced KRW 75.3 billion, about 67.9% of the quarter's sales. Czech sales rose 22.5%, leading growth within Europe.

Balance sheet and cash generation

At the end of 2025, total equity was KRW 497.5 billion and total liabilities KRW 191.8 billion, a debt-to-equity ratio of 38.5%. Operating cash flow was KRW 60.3 billion in 2025, the highest in the 2022 to 2025 period. Second-quarter 2026 operating profit reached KRW 24.5 billion.

09

Bear factors

Operating gains did not reach net profit

The third quarter of 2026 produced a KRW 3.6 billion net loss attributable to controlling shareholders, down from KRW 22.4 billion in the second quarter. Operating profit nevertheless grew year on year over the same period.

According to the provisional third-quarter release, pre-tax results before tax expense showed a loss of about KRW 2.1 billion.

Multi-year decline in profitability

The operating margin fell each year, from 20.2% in 2022 to 16.6%, 14.0% and 12.8% in 2025. Net profit attributable to controlling shareholders was KRW 40.1 billion in 2025, down 27.2%. Revenue rose 10.7% in 2025, but profitability did not improve.

Decline in the core 3D product line

On a standalone basis in the third quarter of 2026, 3D product sales fell 11% to KRW 35.6 billion. 3D diagnostic equipment made up 64.63% of sales in 2024, so reliance on the core line is high. Exports were 92.6% of sales in 2025, leaving the company highly exposed to overseas demand.

10

Risk factors

Product mix shift

If the pattern of falling 3D sales alongside rapid growth in other products persists, the profit structure could change. The margin profile of the other product lines relative to 3D is not broken out in the available data. The effect of the mix shift on the operating margin should be checked in the next annual report.

Overseas dependence and currency

Exports exceed 90% of sales, so overseas conditions drive most of the results. Regional regulation, changes at distribution partners and currency moves can affect both sales and won-converted profit. With Europe and the United States representing large shares, demand in those regions is the key variable.

Execution risk in new initiatives

The mid-term strategy announced in September 2026 aims to extend into prevention and management by combining AI and software. R&D spending was 3.21% of sales in 2025, a meaningful commitment. Whether the new areas generate returns on that spending remains to be seen.

11

What to watch next

  1. Around February 2027

    Provisional annual results for 2026. Check whether net profit attributable to controlling shareholders recovers after the third-quarter loss and how the operating margin compares with 12.8% in 2025.

  2. March 31, 2027

    Filing deadline for the 2026 annual business report. Review how annual revenue compares with KRW 426.4 billion in 2025 and check product mix and regional shares.

  3. May 15, 2027

    Filing deadline for the first-quarter 2027 report. Compare against first-quarter 2026 operating profit of KRW 11 billion and net profit attributable to controlling shareholders of KRW 14.5 billion.

12

Overall view

Value Added Technology reported third-quarter 2026 revenue of KRW 110.9 billion, up 10.8%, and operating profit of KRW 15.6 billion, up 25.5%, so profit grew faster than sales.

The same quarter brought a KRW 3.6 billion net loss attributable to controlling shareholders, meaning the operating improvement did not carry through to net profit.

On an annual basis, 2025 revenue of KRW 426.4 billion marked a second consecutive year of growth, but the operating margin declined from 20.2% in 2022 to 12.8% in 2025. Europe, the United States and South America together account for about 67.9% of sales, which is both a strength and a concentration risk.

Within products, the drop in 3D sales alongside rapid growth in other lines makes the effect of the mix shift on profitability a central question. On the balance sheet, a debt-to-equity ratio of 38.5% and operating cash flow of KRW 60.3 billion in 2025 provide a cushion.

The share price sits well below book value per share, but earnings-based multiples are sensitive to swings in profit. The next points to check are the 2026 annual results and business report, followed by the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.fnguide.com
  2. pinpointnews.co.kr
  3. vatechnetworks.com
  4. comp.fnguide.com
  5. newstap.co.kr
  6. file.alphasquare.co.kr
  7. ssl.pstatic.net
  8. vegannews.co.kr
  9. edaily.co.kr
  10. wcomp.fnguide.com
  11. monews.co.kr
  12. newstown.co.kr
  13. rapportian.com
  14. pinpointnews.co.kr
  15. vegannews.co.kr
  16. edaily.co.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis